Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, which is in Phase 2a clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response. Kiniksa Pharmaceuticals, Ltd. was incorporated in 2015 and is based in Hamilton, Bermuda.
Revenue of Kiniksa Pharmaceuticals, Ltd. (KNSA)
Revenue in 2023 (TTM): $270.26 M
According to Kiniksa Pharmaceuticals, Ltd.'s latest financial reports the company's current revenue (TTM) is $270.26 M. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Revenue history of Kiniksa Pharmaceuticals, Ltd.
Annual Revenue
| Year | Revenue | Gross Profit | Ebitda | Income Before Tax | Net Income |
|---|---|---|---|---|---|
| 2023 | $270.26 M | $213.74 M | $-22,855,000 | $-16,652,000 | $14.08 M |
| 2022 | $220.18 M | $173.21 M | $9.77 M | $11.03 M | $183.36 M |
| 2021 | $38.54 M | $29.44 M | $-154,281,000 | $-156,539,000 | $-157,924,000 |
| 2020 | $ | $-3,805,000 | $-152,424,000 | $-156,229,000 | $-161,381,000 |
| 2019 | $ | $-3,279,000 | $-167,895,000 | $-163,914,000 | $-161,867,000 |
| 2018 | $ | $-286,000 | $-107,874,000 | $-103,441,000 | $-103,227,000 |
| 2017 | $ | $-28,000 | $-65,372,000 | $-64,871,000 | $-64,873,000 |
| 2016 | $ | $-22,000 | $-23,980,000 | $-23,937,000 | $-23,973,000 |